The committee gave a due pass to a committee substitute of SB20 to reduce the frequency insurers can demand prior authorization for chronic maintenance drugs for serious mental illness; insurers, clinicians, and patient advocates debated safety, administrative burden, and whether an amendment shortening review periods should be adopted.